// App-Quantinova.ai

1008 : Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.

Researchers

Presenter

  • Sylvia Adams

Principal Investigators

  • Hope S. Rugo

  • Eric P. Winer

  • Delphine Loirat

  • Ahmad Awada

  • David W. Cescon

  • Hiroji Iwata

  • Mario Campone

  • Rita Nanda

  • Rina Hui

  • Giuseppe Curigliano

  • Deborah Toppmeyer

  • Joyce O'Shaughnessy

  • Sherene Loi

  • Shani Paluch-Shimon

  • Deborah Card

  • Jing Zhao

  • Vassiliki Karantza

  • Javier Cortes

Medical Centers

  • Perlmutter Cancer Center, New York University School of Medicine, New York, NY

  • Barts Health NHS Trust, London, United Kingdom

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Dana-Farber Cancer Institute, Boston, MA

  • Institut Curie, Paris Cedex, France

  • Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

  • The University of Chicago Medical Center, Chicago, IL

  • Westmead Hospital, Westmead, Australia

  • Istituto Europeo di Oncologia, Milano, Italy

  • Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

  • Baylor University Medical Center, Dallas, TX

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Sheba Medical Center Hospital at Tel HaShomer, Tel-Hashomer, Israel

  • Merck & Co., Inc., Kenilworth, NJ

  • Vall dHebron University Hospital Institute of Oncology (VHIO) and Ramon y Cajal University Hospital, Madrid, Spain

Locations

  • Canada

  • Japan

  • Italy

  • Spain

  • United Kingdom

  • Australia

  • United States

  • Israel

  • France

  • Belgium

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT02447003ORR

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved